Table 4.

Summary of studies on menopausal hormonal therapy (MHT).

Study, Year	Outcome
Yu Jin Kim 2021	Sample size and subject: 1,411,215 women (45 years or older) with or without HT medication history. Findings: 381,306 women were associated with a remarkably reduced risk of dementia (NDDs), and the more significant duration of therapy was associated with a reduced risk of NDDs, including AD and dementia.
Yoo, 2020	Sample size and subject: 4,696, 633 postmenopausal women without dementia. Findings: 212,227 incident cases of dementia; the use of hormone replacement therapy and oral contraceptive independently reduced the dementia risk by 15% and 10%, respectively.
Han, 2020	Sample size: 13,110 Findings: TIB use was not remarkably associated with the risk of dementia. A total of 940 incident cases of dementia, with 883 cases of AD and 206 VD.
Paganini-Hil, 2020	Sample size and subject: 424 women without dementia Findings: 209 incident cases of dementia; no individual menopausal, reproductive, menstrual, or estrogen replacements were linked with the risk of incident dementia after age 90.